Consultation Launched on Proposed Changes to the ABPI Code of Practice for the Pharmaceutical Industry?
Consultation launched on proposed changes to the ABPI Code of Practice for the Pharmaceutical Industry and the Constitution and Procedure for the Prescription Medicines Code of Practice Authority
Changes are proposed to the 2014 ABPI Code of Practice for the Pharmaceutical Industry and the PMCPA Constitution and Procedure.
There are a number of reasons for the changes including the work done by the group established by the ABPI Board to review the Code. Additional changes are also needed to implement fully the European Federation of Pharmaceutical Industry Associations (EFPIA) Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations.
Updates to the EFPIA Disclosure Code and the EFPIA Code on the Promotion of Prescription-Only Medicines to, and Interactions with, Healthcare Professionals were agreed at the EFPIA General Assembly on 6 June 2014. The Medicines and Healthcare Products Regulatory Agency (MHRA) consultation as part of the red tape challenge and the regular update of the Code and its operation have also resulted in proposals.
Key proposals relate to changes around transparency and disclosure of some payments to health professionals including the creation of a central platform for disclosure, updates to certification requirements for Joint Working and the proposed introduction of a Product Related Service Provison.
The attached documents set out proposals to amend the ABPI Code and the Constitution and Procedure.
1. Proposals to amend the ABPI Code of Practice for the Pharmaceutical Industry
2. Proposals to amend the PMCPA Constitution and Procedure
3. EFPIA Disclosure Code
4. EFPIA template
5. EFPIA HCP Code
6. Draft template (UK amendments to EFPIA version).
The timetable is as follows:
Friday, 11 July
Proposals sent to ABPI members, non members that have agreed to comply with the Code and those organisations cited in the PMCPA Constitution and Procedure. Proposals put on the PMCPA website for public consultation.
Friday, 5 September
Consultation closes.
Tuesday, 7 October
Final proposals to be agreed by the ABPI Board of Management.
Thursday, 20 November
Proposals to be before the ABPI Half-Yearly General Meeting.
Thursday, 1 January 2015
New Code to come into operation.
Related News
-
News Introducing the Pharmaceutical Sustainability Ecosystem from CPHI
The Sustainability Collective from CPHI unveils the groundbreaking Pharmaceutical Sustainability Ecosystem to drive pharmaceutical knowledge sharing, connection, and collaboration in order to change the face of sustainability in pharmceutical... -
News US Government shutdown leads to the FDA grinding to a halt
The US Congress reached a deadlock after not being able to come to an agreement regarding funding, specifically reaching an impasse when Republicans and Democrats were unable to reach an agreement regarding Obamacare subsidies. The resulting shutdown o... -
News Biosimilars for the better: an expert view from Ecolab
Ecolab expert Renato Azevedo shares his insights on the current state of the biosimilars market in pharmaceuticals, after a high number of biosimilar drug approvals throughout the year confirming the shift of focus in this field. -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News CPHI Podcast Series: US drug policy – exploring the executive orders
The latest episode of the CPHI Podcast Series provides a timely overview of the recent policy changes in the USA, with President Trump signing excecutive orders to change drug pricing under a 'Most Favoured Nation' scheme.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ...